PMO Interview with the Innovator Series: Volume 10

Frontline Therapy Setting

Dixie-Lee Esseltine, MD and George Mulligan, PhD discuss the challenges and gaps in the current standards of care of patients with multiple myeloma, including oral and intravenous treatment options in the frontline therapy setting.

James F. Donohue, MD
Video Categories: PMO Interview with the Innovator Series: Volume 10

Relapsed/Refractory Setting

Dixie-Lee Esseltine, MD and George Mulligan, PhD discuss the challenges in the current standards of care of patients with multiple myeloma in the relapse setting.

James F. Donohue, MD
Video Categories: PMO Interview with the Innovator Series: Volume 10

Maintenance Setting

Dixie-Lee Esseltine, MD and George Mulligan, PhD discuss the challenges in the current standards of care of patients with multiple myeloma in the maintenance setting.

James F. Donohue, MD
Video Categories: PMO Interview with the Innovator Series: Volume 10

Overview of Ixazomib

Dixie-Lee Esseltine, MD provides a brief overview of the dosing schedule and indications of ixazomib. She also reviews the phase 3 clinical trials of ixazomib that are currently ongoing.

James F. Donohue, MD
Video Categories: PMO Interview with the Innovator Series: Volume 10

Treatment Regimen for Patients with Multiple Myeloma

Dixie-Lee Esseltine, MD and George Mulligan, PhD explain ixazomib’s mechanism of action and how the drug may fit into the treatment regimen for patients upon approval and beyond.

James F. Donohue, MD
Video Categories: PMO Interview with the Innovator Series: Volume 10

Aspirations for the Launch of Ixazomib

Ixazomib may have the potential for great combinability with other drugs, according to Dixie-Lee Esseltine, MD and George Mulligan, PhD. Combination therapy improves compliance, adherence, and quality of life among patients.

James F. Donohue, MD
Video Categories: PMO Interview with the Innovator Series: Volume 10

Challenges with Oral Oncolytics

Dixie-Lee Esseltine, MD and George Mulligan, PhD address the challenges that they foresee for patients as more oral oncolytics are developed.

James F. Donohue, MD
Video Categories: PMO Interview with the Innovator Series: Volume 10

Takeda Oncology Resources for Meeting the Challenges with Oncolytics

Dixie-Lee Esseltine, MD and George Mulligan, PhD describe how Takeda Oncology is working to provide resources that assist patients in understanding their disease and their goals of treatment

James F. Donohue, MD
Video Categories: PMO Interview with the Innovator Series: Volume 10

Challenges with Oral Oncolytics for Healthcare Practitioners

As more oral oncolytics are developed, choosing the right regimen for prolonged disease-free survival presents a major patient management challenge. Dixie-Lee Esseltine, MD and George Mulligan, PhD explain that healthcare practitioners will have to make informed choices by balancing information emerging across similar trials.

James F. Donohue, MD
Video Categories: PMO Interview with the Innovator Series: Volume 10

Challenges with Oral Oncolytics for Payers and Practice Managers

Dixie-Lee Esseltine, MD and George Mulligan, PhD shed light on the challenges that payers and practice managers will face as more oncolytics come into the market.

James F. Donohue, MD
Video Categories: PMO Interview with the Innovator Series: Volume 10

Sign me up!